A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer

Trial Profile

A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs ALT 801 (Primary) ; Gemcitabine
  • Indications Bladder cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
    • 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top